Search

Your search keyword '"Lowenberg, B."' showing total 16 results
Start Over Author "Lowenberg, B." Journal haematologica
16 results on '"Lowenberg, B."'

3. Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations

Author

Abbas, S., primary, Sanders, M. A., additional, Zeilemaker, A., additional, Geertsma-Kleinekoort, W. M. C., additional, Koenders, J. E., additional, Kavelaars, F. G., additional, Abbas, Z. G., additional, Mahamoud, S., additional, Chu, I. W. T., additional, Hoogenboezem, R., additional, Peeters, J. K., additional, van Drunen, E., additional, van Galen, J., additional, Beverloo, H. B., additional, Lowenberg, B., additional, and Valk, P. J. M., additional

Published
2014
Full Text
View/download PDF

6. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia

Author

Deenik, W., primary, Janssen, J. J. W. M., additional, van der Holt, B., additional, Verhoef, G. E. G., additional, Smit, W. M., additional, Kersten, M. J., additional, Daenen, S. M. G. J., additional, Verdonck, L. F., additional, Ferrant, A., additional, Schattenberg, A. V. M. B., additional, Sonneveld, P., additional, van Marwijk Kooy, M., additional, Wittebol, S., additional, Willemze, R., additional, Wijermans, P. W., additional, Beverloo, H. B., additional, Lowenberg, B., additional, Valk, P. J. M., additional, Ossenkoppele, G. J., additional, and Cornelissen, J. J., additional

Published
2009
Full Text
View/download PDF

7. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

Author

Cervera, J., primary, Montesinos, P., additional, Hernandez-Rivas, J. M., additional, Calasanz, M. J., additional, Aventin, A., additional, Ferro, M. T., additional, Luno, E., additional, Sanchez, J., additional, Vellenga, E., additional, Rayon, C., additional, Milone, G., additional, de la Serna, J., additional, Rivas, C., additional, Gonzalez, J. D., additional, Tormo, M., additional, Amutio, E., additional, Gonzalez, M., additional, Brunet, S., additional, Lowenberg, B., additional, and Sanz, M. A., additional

Published
2009
Full Text
View/download PDF

8. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis

Author

Montesinos, P., primary, Diaz-Mediavilla, J., additional, Deben, G., additional, Prates, V., additional, Tormo, M., additional, Rubio, V., additional, Perez, I., additional, Fernandez, I., additional, Viguria, M., additional, Rayon, C., additional, Gonzalez, J., additional, de la Serna, J., additional, Esteve, J., additional, Bergua, J. M., additional, Rivas, C., additional, Gonzalez, M., additional, Gonzalez, J. D., additional, Negri, S., additional, Brunet, S., additional, Lowenberg, B., additional, and Sanz, M. A., additional

Published
2009
Full Text
View/download PDF

12. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Author

Liso, A., primary, Castiglione, F., additional, Cappuccio, A., additional, Stracci, F., additional, Schlenk, R. F., additional, Amadori, S., additional, Thiede, C., additional, Schnittger, S., additional, Valk, P. J.M., additional, Dohner, K., additional, Martelli, M. F., additional, Schaich, M., additional, Krauter, J., additional, Ganser, A., additional, Martelli, M. P., additional, Bolli, N., additional, Lowenberg, B., additional, Haferlach, T., additional, Ehninger, G., additional, Mandelli, F., additional, Dohner, H., additional, Michor, F., additional, and Falini, B., additional

Published
2008
Full Text
View/download PDF

14. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Author

Barragán E, Montesinos P, Camos M, González M, Calasanz MJ, Román-Gómez J, Gómez-Casares MT, Ayala R, López J, Fuster Ó, Colomer D, Chillón C, Larrayoz MJ, Sánchez-Godoy P, González-Campos J, Manso F, Amador ML, Vellenga E, Lowenberg B, and Sanz MA

Subjects
Adolescent, Adult, Aged, Child, Female, Humans, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute mortality, Male, Middle Aged, Prognosis, Remission Induction, Survival Analysis, Treatment Outcome, Young Adult, Anthracyclines therapeutic use, Antineoplastic Agents therapeutic use, Leukemia, Promyelocytic, Acute drug therapy, Mutation, Tretinoin therapeutic use, fms-Like Tyrosine Kinase 3 genetics
Abstract

Background: Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established., Design and Methods: We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatías Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005., Results: FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) patients had internal tandem duplication and D835 mutations, respectively. Internal tandem duplication was correlated with higher white blood cell and blast counts, lactate dehydrogenase, relapse-risk score, fever, hemorrhage, coagulopathy, BCR3 isoform, M3 variant subtype, and expression of CD2, CD34, human leukocyte antigen-DR, and CD11b surface antigens. The FLT3-D835 mutation was not significantly associated with any clinical or biological characteristic. Univariate analysis showed higher relapse and lower survival rates in patients with a FLT3-internal tandem duplication, while no impact was observed in relation to FLT3-D835. The prognostic value of the FLT3-internal tandem duplication was not retained in the multivariate analysis., Conclusions: FLT3-internal tandem duplication mutations are associated with several hematologic features in acute promyelocytic leukemia, in particular with high white blood cell counts, but we were unable to demonstrate an independent prognostic value in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Published
2011
Full Text
View/download PDF

15. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.

Author

Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, and Sanz MA

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Chromosomes, Human, Pair 15 genetics, Chromosomes, Human, Pair 17 genetics, Cohort Studies, Female, Follow-Up Studies, Humans, In Situ Hybridization, Fluorescence, Leukemia, Promyelocytic, Acute pathology, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local pathology, Oncogene Proteins, Fusion genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Remission Induction, Reverse Transcriptase Polymerase Chain Reaction, Survival Rate, Translocation, Genetic, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Chromosome Aberrations, Leukemia, Promyelocytic, Acute drug therapy, Leukemia, Promyelocytic, Acute genetics, Tretinoin therapeutic use
Abstract

Background: Acute promyelocytic leukemia is a subtype of acute myeloid leukemia characterized by the t(15;17). The incidence and prognostic significance of additional chromosomal abnormalities in acute promyelocytic leukemia is still a controversial matter., Design and Methods: Based on cytogenetic data available for 495 patients with acute promyelocytic leukemia enrolled in two consecutive PETHEMA trials (LPA96 and LPA99), we analyzed the incidence, characteristics, and outcome of patients with acute promyelocytic leukemia with and without additional chromosomal abnormalities who had been treated with all-trans retinoic acid plus anthracycline monochemotherapy for induction and consolidation., Results: Additional chromosomal abnormalities were observed in 140 patients (28%). Trisomy 8 was the most frequent abnormality (36%), followed by abn(7q) (5%). Patients with additional chromosomal abnormalities more frequently had coagulopathy (P=0.03), lower platelet counts (P=0.02), and higher relapse-risk scores (P=0.02) than their counterparts without additional abnormalities. No significant association with FLT3/ITD or other clinicopathological characteristics was demonstrated. Patients with and without additional chromosomal abnormalities had similar complete remission rates (90% and 91%, respectively). Univariate analysis showed that additional chromosomal abnormalities were associated with a lower relapse-free survival in the LPA99 trial (P=0.04), but not in the LPA96 trial. However, neither additional chromosomal abnormalities overall nor any specific abnormality was identified as an independent risk factor for relapse in multivariate analysis., Conclusions: The lack of independent prognostic value of additional chromosomal abnormalities in acute promyelocytic leukemia does not support the use of alternative therapeutic strategies when such abnormalities are found.

Published
2010
Full Text
View/download PDF

16. Strategies in the treatment of acute myeloid leukemia.

Author

Lowenberg B

Subjects
Acute Disease, Adolescent, Adult, Age Factors, Aged, Animals, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Disease-Free Survival, Granulocyte Colony-Stimulating Factor therapeutic use, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Humans, Leukemia, Experimental drug therapy, Leukemia, Myeloid classification, Leukemia, Myeloid genetics, Leukemia, Myeloid surgery, Middle Aged, Oncogene Proteins, Fusion analysis, Oncogene Proteins, Fusion genetics, Peripheral Blood Stem Cell Transplantation, Randomized Controlled Trials as Topic, Remission Induction, Transplantation, Autologous, Transplantation, Homologous, Treatment Outcome, Leukemia, Myeloid drug therapy
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results